Stockreport

Can-Fite to Advance New Veterinary Partnership Opportunities for Namodenoson at the BioFIT 2025 Conference

Can-Fite Biopharma Ltd Sponsored ADR (Israel)  (CANF) 
NASDAQ:AMEX Investor Relations: ir.canfite.com
PDF Namodenoson, a Phase III cancer drug has strong potential in veterinary oncology, a market projected to reach $3.1 billion by 2030 Piclidenoson is currently in developm [Read more]